eht 0202
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00880412)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- GABA receptor beta-3 subunitPOSITIVE ALLOSTERIC MODULATOR
GABRB3 positive allosteric modulator
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)c1cnc2c(cnn2CC)c1NN=C(C)C- Mol. weight
- 289.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL356388 ↗
Also known as
- eht 0202
- eht 0202
- eht-0202
- eht-0202
- etazolate
- etazolate
- etazolate
- sq-20009
- sq-20009
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00880412 | Phase 2 | Apr 1, 2008 | Exonhit, University of Toulouse |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Exonhit | For profit | 1 | 1 | 1 | 2008 |
| University of Toulouse | Academic/Hospital | 1 | 0 | 1 | 2008 |
2 organizations
Page 1 / 1